{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:06:24Z","timestamp":1773396384454,"version":"3.50.1"},"reference-count":17,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nephrol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n                  <jats:p>Primary membranous nephropathy (MN) is a major cause of nephrotic syndrome in adults, characterized by immune complex formation on the outer side of the glomerular basement membrane. Primary MN accounts for 80% of the cases, and 20% cases are associated with a secondary etiology. While immunosuppressive therapy has improved patient outcomes in MN, the clinical profile and treatment outcomes of MN in our patient population have not been previously studied.<\/jats:p>\n                  <jats:p>AIM<\/jats:p>\n                  <jats:p>To investigate the clinicopathological profile and outcomes of primary MN patients. We included consenting patients aged \u2265 18 years with primary MN and excluded those with end-stage kidney disease, pregnancy, or secondary MN.<\/jats:p>\n                  <jats:p>METHODS<\/jats:p>\n                  <jats:p>This study approved by the institutional ethics committee, was conducted at the Department of Nephrology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India. Detailed history, physical examination, laboratory investigations [including 24-hour urinary protein, kidney and liver function tests, and anti-phospholipase A2 receptor (PLA2R) antibody levels], and screening for secondary etiologies were performed. Renal biopsy tissues were examined using light microscopy, immunofluorescence, immunohistochemistry for PLA2R, thrombospondin type 1 domain-containing 7A, neural epidermal growth factor-like 1 (NELL-1), exostosin 1, exostosin 2, and electron microscopy. Patients were risk-stratified based on proteinuria, kidney function, and serum anti-PLA2R antibody levels. Remission, relapse, and resistant disease were defined by specific proteinuria and albumin criteria.<\/jats:p>\n                  <jats:p>RESULTS<\/jats:p>\n                  <jats:p>Of 46 patients, 60.9% were female, with a mean age of 43.8 \u00b1 13.7 years. The mean proteinuria was 5.8 \u00b1 3.2 g\/day, mean serum albumin was 2.5 \u00b1 0.39 g\/dL, and mean estimated glomerular filtration rate was 99.8 \u00b1 26.6 mL\/minute\/1.73 m2. Edema was the most common symptom (100%), and hypertension was the most frequent comorbidity (37%). Serum anti-PLA2R antibodies were positive in 39.1% of patients. On immunohistochemistry, 58.7% were tissue PLA2R positive and 17.4% were NELL-1 positive. At baseline, 71.1% of patients were in the high-risk category. Initial non-immunosuppressive supportive care was given to 84.8% of patients, with 23.08% achieving remission. Among those receiving immunosuppressive therapy, 72.2% on modified Ponticelli regimen and 85.7% on other regimens achieved remission at 6 months (P  = 0.432). At 12 months, 82.9% of patients on immunosuppressive therapy achieved remission. Both modified Ponticelli and other immunosuppressive regimens significantly improved proteinuria and serum albumin at 12 months (P  &lt; 0.0001).<\/jats:p>\n                  <jats:p>CONCLUSION<\/jats:p>\n                  <jats:p>PLA2R-associated MN was the most common form of MN, followed by NELL-1. Primary MN prevalence was highest in the fifth and sixth decades of life, with a slight female preponderance observed in this study. Most patients belonged to the high-risk group. Immunosuppression led to complete remission in over 80% of patients, with no significant difference in remission rates between different immunosuppressive agents. This study provides initial insights into MN in the local patient population, despite its limitations of being a single-center observational study with a relatively small sample size and short follow-up.<\/jats:p>","DOI":"10.5527\/wjn.v15.i1.113303","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:00Z","timestamp":1773392220000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical profile and outcome of primary membranous nephropathy: A tertiary care center experience from North India"],"prefix":"10.5527","volume":"15","author":[{"given":"Muzamil Ahmad","family":"Wani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad Iqbal","family":"Rather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ashraf","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzafar Maqsood","family":"Wani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imtiyaz Ahmad","family":"Wani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayees Yousuf","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manzoor Ahmad","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.611317"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116"},{"key":"B3","unstructured":"Johnson RJ, Feehally J, Floege J.   Membranous nephropathy. Chapter 20. In: Comprehensive Clinical Nephrology. 5th ed. Philadelphia: Saunders, 2015: 239-251"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020071082"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70316-7"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070776"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00303-z"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199592548.001.0001"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2022.43.9.20220459"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90568-5"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071343"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.06.032"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.15171\/jnp.2019.25"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.014"}],"container-title":["World Journal of Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v15\/i1\/113303.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v15\/i1\/113303.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:18Z","timestamp":1773392238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-6124\/full\/v15\/i1\/113303.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":17,"journal-issue":{"issue":"1"},"alternative-id":["113303"],"URL":"https:\/\/doi.org\/10.5527\/wjn.v15.i1.113303","relation":{},"ISSN":["2220-6124"],"issn-type":[{"value":"2220-6124","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}